Summary of significant transactions - Terms of the collaboration relating to our drug discovery platform (Details) - Gilead collaboration agreement for drug discovery platform |
Jul. 14, 2019
USD ($)
|
|---|---|
| Summary Of Significant Transaction [line items] | |
| Programs Option Right Sharing Period | 10 years |
| Opt-In Payments to be Received for Each program collaboration Opted | $ 150,000,000 |
| Minimum | Outside Europe | |
| Summary Of Significant Transaction [line items] | |
| Tiered Royalties Percentage on Net Sales | 20.00% |
| Maximum | Outside Europe | |
| Summary Of Significant Transaction [line items] | |
| Tiered Royalties Percentage on Net Sales | 24.00% |